RT/TMZ/BEV - Rencontres Cancero 2013

Modérateurs : Pr.Marc Spielmann et Pr.Hassane Errihani
•Les Immanquables dans le colo-rectal
Pr. Eric Van Cutsem
Pr. Blaha Larbaoui
•Les Immanquables en onco-gynécologie
Pr. Kamel Bouzid
Pr. Patricia Pautier
•Les Immanquables dans le cancer du sein
Pr. Farhat Ben Ayed
Pr. Thierry Petit
•Les Immanquables dans les glioblastomes
Dr. Mounir Bachouchi
Pr. Olivier Chinot

Cancers colorectaux
Pr Eric Van Cutsem et Pr Blaha Larbaoui

Maintenance treatment with capecitabine +
bevacizumab besus observation after induction
treatment with chemotherapy
+ bevacizumab in metastatic colorectal cancer
Phase 3 CAIRO3 study of Dutch Colorectal Cancer Groupe (DCCG)
Miriam Koopman, L Simkens, A ten Tije, G Creemers, O looxveld, F de Jongh, F Erdkamp,
Z erjavec, A van der Torren, J van der Hoeven, P Nieboer, J Braun, R Jansen, J Haasjes, A Cats, J
Wals, L Mol, O Dalesio, H van Tinteren, C Punt

•Optimox : maintenance with 5FU/LV: longer PFS
•Coin, Nordic, Giscad, CONcePt : intermittent treatment may be an option
•Macro : maintenance with bevacizumab may be an appropriate option
following induction Xelox-bevacizumab
•DREAM-GERCOR : CT + bev. bevacizumab ±erlotinib (n=650):
longer PFS for combination
•Ongoing studies with bevacizumab:
•SAKK : CT + bev. bevacizumab vs no treatment (n=470) ASCO 2013
•CAIRO-3 : Xelox + bev. capecitabine + bevacizumab vs no treatment
(n=635) ASCO 2013
•AIO : oxali/FU + bev. FU/bev. vs bev. vs no treatment (n=456)
Metastatic Colorectal Cancer maintenance trials :
from ‘stop and go’ to continuation